A New Measure of Child-Reported Symptomatic Toxicities of Cancer Treatment: Introducing Pediatric PRO-CTCAE®

March 26, 2020
2:00PM – 3:00PM ET


NCI’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) was developed to capture symptomatic toxicity by patient self-report in cancer clinical trials. A pediatric version of PRO-CTCAE (Ped-PRO-CTCAE®) is now available to enable self-reporting of symptomatic adverse events by children and adolescents.

In this webinar speakers and discussants


Pamela S. Hinds, PhD, RN, FAAN
Children's National Hospital

Molly McFatrich, MPH
Duke University School of Medicine

Bryce B. Reeve, PhD
Duke University School of Medicine


David R. Freyer, DO, MS
Children's Hospital Los Angeles
USC Norris Comprehensive Cancer Center

Gregory H. Reaman, MD
US Food & Drug Administration

Douglas S. Hawkins, MD
Seattle Children's Hospital


Sandra A. Mitchell, PhD, CRNP, FAAN
National Cancer Institute

Intended Audience

Extramural investigators at junior, mid, and senior levels.

Suggested Readings

Last Updated: 28 Jan, 2022